REGN
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- CHMP recommends EU approval of an updated Libtayo (cemiplimab) dosing regimen across all approved cancer indicationsOct 16, 2026
- Regeneron reports no new heterotopic ossification lesions in adults with fibrodysplasia ossificans progressiva during the OPTIMA trial extension of Pasatru (garetosmab-grts)Oct 12, 2026
- Regeneron presents clinical advances across multiple cancers and cancer-related complications at ESMO 2026Oct 6, 2026
- Phase 2 COURAGE trial shows trevogrumab prevents lean mass and muscle loss associated with GLP-1 receptor agonist-induced weight reductionOct 1, 2026
- Ubamatamab (MUC16xCD3) demonstrates a high rate of durable responses in an initial study of advanced low-grade serous ovarian cancerOct 1, 2026